[Corrections] Correction to Lancet Oncol 2020; 21: 671–84

January, 01, 2024 | Select Oncology Journal Articles

Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21: 671–84—In this Article, the fourth sentence of the Study design and participants section should read, “Patients were also required to have adequate hepatic and renal function (total bilirubin <1·5×upper limit of normal [ULN], or <2·5×ULN for Gilbert syndrome or a disease involving the liver[…])”. This correction has been made to the online version as of January 2, 2023.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy